IP Library Granted Patent US 10,399,994
Granted Patent B2
US 10,399,994 · App. 15/547,438 · Granted Sep 3, 2019

Compounds and methods for preventing or treating sensory hair cell death

Inventors: Julian Simon (Seattle, WA); Graham Johnson (Sanbornton, NH); Edwin W. Rubel (Seattle, WA); David W. Raible (Seattle, WA); Mario D. Gonzalez (Winchester, MA); Peter C. Meltzer (Lexington, MA); Weishi Miao (Winchester, MA)
Assignees: University of Washington; Oricula Therapeutics LLC; Fred Hutchinson Cancer Research Center
C07D495/18A61K31/439A61K31/7036A61P27/00Y02A50/411
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,399,994
App. No.
15/547,438
Granted
Sep 3, 2019
Kind
B2
Abstract

Disclosed herein are compounds, and pharmaceutical compositions that include such compounds, for preventing or treating hearing loss. The compounds and pharmaceutical compositions described herein prevent or treat hair cell death. In addition, the compounds and pharmaceutical compositions described herein protect against kidney damage in an individual receiving an aminoglycoside antibiotic. Methods of using the compounds, alone or in combination with other therapeutic agents, are also disclosed.

Claims (10)

1. A method for preventing and/or protecting against sensory hair cell death associated with exposure to an ototoxic agent in an individual comprising administering to the individual a therapeutically effective amount of:

or a pharmaceutically acceptable salt thereof.

2. The method of claim 1 , wherein the ototoxic agent is an aminoglycoside antibiotic, chemotherapeutic agent, loop diuretic, antimalarial sesquiterpene lactone endoperoxide, antimalarial quinine, salicylate, or interferon polypeptide.

3. The method of claim 2 , wherein the ototoxic agent is an aminoglycoside antibiotic.

4. The method of claim 3 , wherein the aminoglycoside antibiotic is selected from streptomycin, neomycin, framycetin, paromomycin, paromomycin sulfate, ribostamycin, kanamycin, amikacin, arbekacin, bekanamycin, dibekacin, tobramycin, spectinomycin, hygromycin B, gentamicin, netilmicin, sisomicin, isepamicin, verdamicin, and astromicin.

5. The method of claim 4 , wherein the aminoglycoside antibiotic is streptomycin.

6. The method of claim 4 , wherein the aminoglycoside antibiotic is neomycin.

7. The method of claim 4 , wherein the aminoglycoside antibiotic is amikacin.

8. The method of claim 2 , wherein the ototoxic agent is a chemotherapeutic agent.

9. The method of claim 8 , wherein the chemotherapeutic agent is cisplatin or carboplatin.

Assignments (5)
MERGER AND CHANGE OF NAME Recorded Jun 8, 2022
From: FRED HUTCHINSON CANCER RESEARCH CENTER; SEATTLE CANCER CARE ALLIANCE
To: FRED HUTCHINSON CANCER CENTER
Reel/Frame 060838/0852 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 9, 2018
From: SIMON, JULIAN
To: FRED HUTCHINSON CANCER RESEARCH CENTER
Reel/Frame 045158/0082 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 9, 2018
From: JOHNSON, GRAHAM; GONZALEZ, MARIO D.; MELTZER, PETER C.; MIAO, WEISHI
To: ORICULA THERAPEUTICS LLC
Reel/Frame 045158/0345 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 9, 2018
From: RUBEL, EDWIN W.; RAIBLE, DAVID W.
To: UNIVERSITY OF WASHINGTON
Reel/Frame 045158/0495 →
CONFIRMATORY LICENSE Recorded Aug 18, 2017
From: UNIVERSITY OF WASHINGTON
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 043602/0943 →
Continuity (2)
Provisional Application 62113245 · Feb 6, 2015
Related Publication 20180022756A1 · Jan 25, 2018